81 related articles for article (PubMed ID: 19325102)
1. Biochemistry. Through a mirror, differently.
Sheps JA
Science; 2009 Mar; 323(5922):1679-80. PubMed ID: 19325102
[No Abstract] [Full Text] [Related]
2. Comparison of the inward- and outward-open homology models and ligand binding of human P-glycoprotein.
Pajeva IK; Globisch C; Wiese M
FEBS J; 2009 Dec; 276(23):7016-26. PubMed ID: 19878299
[TBL] [Abstract][Full Text] [Related]
3. Unraveling membrane-mediated substrate-transporter interactions.
Seelig A
Biophys J; 2006 Jun; 90(11):3825-6. PubMed ID: 16565039
[No Abstract] [Full Text] [Related]
4. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding.
Aller SG; Yu J; Ward A; Weng Y; Chittaboina S; Zhuo R; Harrell PM; Trinh YT; Zhang Q; Urbatsch IL; Chang G
Science; 2009 Mar; 323(5922):1718-22. PubMed ID: 19325113
[TBL] [Abstract][Full Text] [Related]
5. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers.
Rezai T; Yu B; Millhauser GL; Jacobson MP; Lokey RS
J Am Chem Soc; 2006 Mar; 128(8):2510-1. PubMed ID: 16492015
[TBL] [Abstract][Full Text] [Related]
6. The flexibility of P-glycoprotein for its poly-specific drug binding from molecular dynamics simulations.
Liu M; Hou T; Feng Z; Li Y
J Biomol Struct Dyn; 2013; 31(6):612-29. PubMed ID: 22888853
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists.
Callahan JF; Bean JW; Burgess JL; Eggleston DS; Hwang SM; Kopple KD; Koster PF; Nichols A; Peishoff CE; Samanen JM
J Med Chem; 1992 Oct; 35(21):3970-2. PubMed ID: 1433204
[No Abstract] [Full Text] [Related]
8. Conformation and Permeability: Cyclic Hexapeptide Diastereomers.
Ono S; Naylor MR; Townsend CE; Okumura C; Okada O; Lokey RS
J Chem Inf Model; 2019 Jun; 59(6):2952-2963. PubMed ID: 31042375
[TBL] [Abstract][Full Text] [Related]
9. Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity.
Cini N; Trabocchi A; Menchi G; Bottoncetti A; Raspanti S; Pupi A; Guarna A
Bioorg Med Chem; 2009 Feb; 17(4):1542-9. PubMed ID: 19195898
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor.
Groll M; Koguchi Y; Huber R; Kohno J
J Mol Biol; 2001 Aug; 311(3):543-8. PubMed ID: 11493007
[TBL] [Abstract][Full Text] [Related]
11. A cyclodecapeptide ligand to vitamin B12.
Duléry V; Uhlich NA; Maillard N; Fluxá VS; Garcia J; Dumy P; Renaudet O; Reymond JL; Darbre T
Org Biomol Chem; 2008 Nov; 6(22):4134-41. PubMed ID: 18972044
[TBL] [Abstract][Full Text] [Related]
12. Do adsorbed drugs onto P-glycoprotein influence its efflux capability?
Ferreira RJ; Ferreira MJ; dos Santos DJ
Phys Chem Chem Phys; 2015 Sep; 17(34):22023-34. PubMed ID: 26235302
[TBL] [Abstract][Full Text] [Related]
13. Conformation and calcium-binding properties of a bicyclic nonapeptide.
Oliva R; Falcigno L; D'Auria G; Zanotti G; Paolillo L
Biopolymers; 2000-2001; 56(1):27-36. PubMed ID: 11582575
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of Selenazole-containing peptides for cocrystallization with P-glycoprotein.
Tao H; Weng Y; Zhuo R; Chang G; Urbatsch IL; Zhang Q
Chembiochem; 2011 Apr; 12(6):868-73. PubMed ID: 21387512
[No Abstract] [Full Text] [Related]
15. Cyclic peptides with a diversely substituted guanidine bridge: solid-phase synthesis and structural analysis.
Touati-Jallabe Y; Chiche L; Hamzé A; Aumelas A; Lisowski V; Berthomieu D; Martinez J; Hernandez JF
Chemistry; 2011 Feb; 17(9):2566-70. PubMed ID: 21294201
[No Abstract] [Full Text] [Related]
16. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?
Loo TW; Clarke DM
Biochem Biophys Res Commun; 2005 Apr; 329(2):419-22. PubMed ID: 15737603
[TBL] [Abstract][Full Text] [Related]
17. Miniaturized proteins: the backbone cyclic proteinomimetic approach.
Kasher R; Oren DA; Barda Y; Gilon C
J Mol Biol; 1999 Sep; 292(2):421-9. PubMed ID: 10493885
[TBL] [Abstract][Full Text] [Related]
18. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.
Przydzial MJ; Pogozheva ID; Bosse KE; Andrews SM; Tharp TA; Traynor JR; Mosberg HI
J Pept Res; 2005 Mar; 65(3):333-42. PubMed ID: 15787963
[TBL] [Abstract][Full Text] [Related]
19. Potent Cyclic Tetrapeptide for Lead Detoxification.
Mohammed TA; Meier CM; Kalvoda T; Kalt M; Rulíšek L; Shoshan MS
Angew Chem Int Ed Engl; 2021 May; 60(22):12381-12385. PubMed ID: 33759306
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein.
Ferreira RJ; Ferreira MJ; dos Santos DJ
J Chem Inf Model; 2013 Jul; 53(7):1747-60. PubMed ID: 23802684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
